Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metastatic Melanoma Treatment in Special Populations.
Miceli M, Boatwright C, Mehnert JM. Miceli M, et al. Among authors: mehnert jm. Cancer J. 2024 Mar-Apr 01;30(2):71-78. doi: 10.1097/PPO.0000000000000701. Cancer J. 2024. PMID: 38527259 Review.
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
Goodman RS, Lawless A, Woodford R, Fa'ak F, Tipirneni A, Patrinely JR, Yeoh HL, Rapisuwon S, Haydon A, Osman I, Mehnert JM, Long GV, Sullivan RJ, Carlino MS, Menzies AM, Johnson DB. Goodman RS, et al. Among authors: mehnert jm. JAMA Netw Open. 2023 Aug 1;6(8):e2327145. doi: 10.1001/jamanetworkopen.2023.27145. JAMA Netw Open. 2023. PMID: 37535354 Free PMC article.
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
Ascierto PA, Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. Ascierto PA, et al. Among authors: mehnert jm. J Transl Med. 2023 Apr 18;21(1):265. doi: 10.1186/s12967-023-04100-y. J Transl Med. 2023. PMID: 37072748 Free PMC article.
Expanding access to early phase trials: the CATCH-UP.2020 experience.
Baranda JC, Diaz FJ, Rubinstein L, Shields AF, Dayyani F, Mehta A, Mehnert JM, Trent J, Mabaera R, Mooney M, Moscow JA, Doroshow J, Waters B, Ivy P, Gore SD, Thomas A. Baranda JC, et al. Among authors: mehnert jm. JNCI Cancer Spectr. 2023 Jan 3;7(1):pkac087. doi: 10.1093/jncics/pkac087. JNCI Cancer Spectr. 2023. PMID: 36525371 Free PMC article.
Where Are All the Women in Industry Advisory Boards?
Shroff RT, Goodman KA, Mehnert JM, Vose JM, Moran SE, Yessaian JL, Baldo L, Alexander BM, Highsmith QB, Mills JM, Kunz PL. Shroff RT, et al. Among authors: mehnert jm. J Clin Oncol. 2023 Mar 20;41(9):1659-1663. doi: 10.1200/JCO.21.02219. Epub 2022 Nov 3. J Clin Oncol. 2023. PMID: 36331246 No abstract available.
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM. Chesney JA, et al. Among authors: mehnert jm. J Immunother Cancer. 2023 May;11(5):e006270. doi: 10.1136/jitc-2022-006270. J Immunother Cancer. 2023. PMID: 37142291 Free PMC article. Clinical Trial.
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Spencer KR, Portal DE, Aisner J, Stein MN, Malhotra J, Shih W, Chan N, Silk AW, Ganesan S, Goodin S, Gounder M, Lin H, Li J, Cerchio R, Marinaro C, Chen S, Mehnert JM. Spencer KR, et al. Among authors: mehnert jm. Oncotarget. 2023 Apr 10;14:302-315. doi: 10.18632/oncotarget.28403. Oncotarget. 2023. PMID: 37036756 Free PMC article. Clinical Trial.
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
Silk AW, O'Day SJ, Kaufman HL, Bryan J, Norrell JT, Imbergamo C, Portal D, Zambrano-Acosta E, Palmeri M, Fein S, Wu C, Guerreiro L, Medina D, Bommareddy PK, Zloza A, Fox BA, Ballesteros-Merino C, Ren Y, Shafren D, Grose M, Vieth JA, Mehnert JM. Silk AW, et al. Among authors: mehnert jm. Cancer Immunol Immunother. 2023 Jun;72(6):1405-1415. doi: 10.1007/s00262-022-03314-1. Epub 2022 Nov 29. Cancer Immunol Immunother. 2023. PMID: 36445410 Free PMC article. Clinical Trial.
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, Cardin DB, Vieito M, Miller RE, Hari Dass P, Orcurto A, Spencer K, Janik JE, Clark J, Condamine T, Pulini J, Chen X, Mehnert JM. Davis EJ, et al. Among authors: mehnert jm. J Immunother Cancer. 2022 Oct;10(10):e004235. doi: 10.1136/jitc-2021-004235. J Immunother Cancer. 2022. PMID: 36316061 Free PMC article. Clinical Trial.
92 results